Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01680887 · ClinicalTrials.gov registry record · Phase 2

A Phase II Trial of Varenicline for the Treatment of Cocaine Dependence

A Phase 2 study, sponsored by University of Pennsylvania.

Completed
Registry status
Phase 2
Development phase
156
Enrollment target

NCT01680887: Completed Phase 2 study, sponsored by University of Pennsylvania.

NCT01680887 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 156 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01680887, a Phase 2 study, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
Phase 2
Development phase
156 participants
Enrollment target

Study Summary

This is a double-blind placebo-controlled clinical trial (n = 156) of varenicline for the treatment of cocaine dependence that utilizes contingency management to promote treatment attendance.

Primary Outcome

Number of subjects with cocaine abstinence as measured through three-times-weekly urine benzoylecgonine (BE) levels in urine drug screen (UDS) and self-reports of use from the Time Line Follow Back. UDS results and TLFB reports combined to yield weekly use/no-use indicators for each week of treatment.

Interventions

  • DRUG Placebo
  • DRUG Varenicline

Trial Details

FieldValue
Enrollment Target 156 participants
Start Date 2012-08
Est. Completion 2019-06
Phase Phase 2
University of Pennsylvania

1,423 total trials

What the finished NCT01680887 record still lists

NCT01680887 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01680887 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01680887 about?

NCT01680887 is a clinical study titled "A Phase II Trial of Varenicline for the Treatment of Cocaine Dependence". This is a double-blind placebo-controlled clinical trial (n = 156) of varenicline for the treatment of cocaine dependence that utilizes contingency management to promote treatment attendance.

What is the current status of trial NCT01680887?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2012-08. Estimated completion is 2019-06.

What interventions are being tested in trial NCT01680887?

The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG).

Who is sponsoring clinical trial NCT01680887?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01680887's enrollment target sits among peer trials

156 445th of 2000 higher than 1,553 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03082755 · 156 participants · Phase 4

    Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease

  • NCT04047628 · 156 participants · Phase 3

    Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

  • NCT04166877 · 156 participants · Phase 4

    Magnesium Infusion for Pain Management in Critically Ill Trauma Patients

  • NCT04533464 · 156 participants · Phase 2

    MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01680887, the US trial registry maintained by the National Library of Medicine. NCT01680887 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.